JD.com Beat Estimates With Higher Profit, Sales
By Tracy Qu
Chinese e-commerce giant JD.com posted a rise in quarterly profit, beating estimates as its core businesses grew despite fierce competition with peers such as Alibaba and PDD.
The Beijing-based company said Thursday that net profit in the first quarter rose 14% from a year earlier to 7.13 billion yuan ($987.7 million). The bottom line beat the consensus estimate of CNY5.26 billion in a FactSet poll of analysts.
JD.com said a focus on user experience helped drive "strong growth" in active users and engagement during the quarter.
Adjusted net profit rose 17% to CNY8.90 billion, beating estimates for CNY7.40 billion. The widely tracked metric excludes share-based compensation and fair-value changes of long-term investments, among other items.
Revenue for the quarter increased 7.0% to CNY260.05 billion, higher than a FactSet estimate for CNY258.47 billion. Retail sales, which make up the bulk of the company's revenue, rose 6.8%, while logistics sales rose 15%.
JD.com is facing stiff competition from rivals including Alibaba and PDD. Earlier this week, Alibaba reported single-digit revenue growth for the March quarter and a 11% decline in adjusted profit.
Write to Tracy Qu at tracy.qu@wsj.com
(END) Dow Jones Newswires
May 16, 2024 07:08 ET (11:08 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
What’s the Difference Between the CPI and PCE Indexes?
-
Micron Earnings: Great Guidance but Stock Now Looks Fairly Valued
-
August PCE Report Forecasts Show More Good News on Inflation
-
AI Stocks May Be Down, but Don’t Count Them Out
-
4 Stocks to Buy as the Fed Cuts Interest Rates
-
Markets Brief: The Uncertain Path to Neutral Interest Rates
-
What’s Happening in the Markets This Week
-
Where Top Stock Fund Managers Are Looking Next After the Fed Rate Cut
-
Our Top Pick for Investing in US Renewable Energy
-
How to Measure a Stock’s Uncertainty
-
How to Determine Whether a Stock Is Cheap, Expensive, or Fairly Valued
-
Why a Company’s Management and Capital Allocation Matter
-
How to Determine What a Stock Is Worth
-
How to Measure a Company’s Competitive Advantage
-
How to Think Like a Stock Analyst
-
How GLP-1 Drugs Like Ozempic Are Boosting Biopharma Stocks